Saturday links: making a decision
Tadas Viskanta
Abnormal Returns
21 hours ago
3 MIN READ
AVs
- Wayve just raised a $1.2 billion funding round. (techcrunch.com)
- Waymo now operates in 10 cities and is planning further expansion. (axios.com)
- What’s going on with Tesla’s ($TSLA) robotaxi efforts? (sherwood.news)
- Why Uber ($UBER) bought Spot Hero. (platformaeronaut.com)
EVs
- Why Lamborghini is cancelling its first EV. (semafor.com)
- There’s two ways to reduce range anxiety. (papers.ssrn.com)
- How electric buses fare in cold climates. (grist.org)
Autos
- American automakers are headed down a dead end with ICEs. (energynow.com)
- State Farm is lowering car insurance rates. (axios.com)
- More evidence that smartphones are a driving distraction. (papers.ssrn.com)
Energy
- The case for leasing solar panels. (npr.org)
- How closed-loop geothermal works. (nytimes.com)
- Why these California farmers favor this big solar project. (npr.org)
Animals
Space
- How many satellites is too many? (sfexaminer.com)
- The FCC has pretty much given up regulating satellites. (wapo.st)
Archaeology
- The Vikings were fare more diverse than previously thought. (science.org)
- How Neanderthal DNA shows up in human DNA. (arstechnica.com)
- This may be a very early precursor to writing. (edition.cnn.com)
Technology
- Apple ($AAPL) needs to copy this privacy feature. (wsj.com)
- The war against PDFs. (economist.com)
- AI has no taste. (spyglass.org)
Behavior
- What it means to matter. (roncharles.substack.com)
- How phones can ruin third spaces. (insidehook.com)
Vaccines
- Moderna’s ($MRNA) combination flu and COVID-19 vaccine got a positive recommendation in Europe. (biopharmadive.com)
- Measles case counts are headed higher. (theatlantic.com)
- Get your shingles vaccine! (arstechnica.com)
- Some in MAHA aren’t just anti-vaxx, they are pro-infection. (theatlantic.com)
Public health
- The ACA helped reduce health coverage gaps. (papers.ssrn.com)
- States are trying to launch or expand public health options. (npr.org)
- What the Surgeon General nominee believes about, you know, medicine. (theatlantic.com)
- More women are skipping on prenatal care. (axios.com)
Medicine
- A primary care physician is a valued commodity. Just ask these small towns. (nytimes.com)
- There are not enough geriatricians. (theconversation.com)
Health
- Cardiovascular disease presents differently in men and women. (statnews.com)
- Eli Lilly’s GLP-1 pill orforglipron outperformed Novo Nordisk’s drug Rybelsus in a head-to-head trial. (biopharmadive.com)
- What are peptides? (npr.org)
Food
- Energy drink makers are now marketing to women. (theatlantic.com)
- Japan’s tea plantations are leaving money on the table. (asia.nikkei.com)
- Why McDonald’s ($MCD) is launching the Big Arch burger. (sherwood.news)
- The administration is relaxing regulations in slaughterhouses. (vox.com)
Sports
- What is the WNBA’s financial situation? It’s hard to tell. (frontofficesports.com)
- ABS could change baseball more than you think. (neilpaine.substack.com)
- Ski resorts increasingly rely on snow making machines. (grist.org)
- Apple ($AAPL) is going all out for its F1 coverage. (frontofficesports.com)
Children
- What should schools being teaching kids about AI? (nytimes.com)
- How kids are getting around school phone bans. (nytimes.com)
Earlier on Abnormal Returns
- What you missed in our Friday linkfest. (abnormalreturns.com)
- Podcast links: talking tech. (abnormalreturns.com)
- Don’t miss a thing! Sign up for our daily e-mail newsletter. (abnormalreturns.com)
Mixed media
Terms and Conditions
This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.
The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.
References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.
Please see disclosures here.
